Literature DB >> 20060108

Baculovirus activates murine dendritic cells and induces non-specific NK cell and T cell immune responses.

Tomoyuki Suzuki1, Myint Oo Chang, Masayuki Kitajima, Hiroshi Takaku.   

Abstract

We previously reported that the baculovirus induced a strong host immune response against infections and malignancies. Among the immune cells, the dendritic cells were most strongly infected and activated by the baculovirus, although the exact mechanism remained unclear. Here, we evaluated the non-specific immune responses of bone marrow-derived dendritic cells (BMDCs) after infection by a wild-type baculovirus. MHC class I and II molecules and co-stimulation molecules (CD40, CD80, and CD86) on BMDCs were up-regulated by baculovirus infection. At the same time, the BMDCs produced pre-inflammatory cytokines (IL-6, IL12p70, and TNF-alpha) and IFN-alpha. NK cells showed IFN-gamma production, CD69 up-regulation, and enhanced cytotoxicity when they were co-cultured with baculovirus-infected BMDCs. T cells showed IFN-gamma production, CD69 up-regulation, and cell proliferation. Ex vivo analysis performed in vitro produced similar results. These findings suggested that baculovirus-infected dendritic cells induce non-specific immune responses and can be used as an immunotherapeutic agent against viral infections and malignancies, together with present therapeutic drug regimens. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20060108     DOI: 10.1016/j.cellimm.2009.12.005

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  14 in total

1.  Induction of antitumor immunity against mouse carcinoma by baculovirus-infected dendritic cells.

Authors:  Tomoyuki Suzuki; Myint Oo Chang; Masayuki Kitajima; Hiroshi Takaku
Journal:  Cell Mol Immunol       Date:  2010-09-27       Impact factor: 11.530

2.  Baculovirus mediated transduction: analysis of vesicular stomatitis virus glycoprotein pseudotyping.

Authors:  Sujit M Kolangath; S H Basagoudanavar; M Hosamani; P Saravanan; R P Tamil Selvan
Journal:  Virusdisease       Date:  2014-10-11

3.  Adaptive immune responses elicited by baculovirus and impacts on subsequent transgene expression in vivo.

Authors:  Wen-Yi Luo; Shih-Yeh Lin; Kai-Wei Lo; Chia-Hsin Lu; Chang-Lin Hung; Chi-Yuan Chen; Chien-Chung Chang; Yu-Chen Hu
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

4.  A tumor lysate is an effective vaccine antigen for the stimulation of CD4(+) T-cell function and subsequent induction of antitumor immunity mediated by CD8(+) T cells.

Authors:  Mamoru Kawahara; Hiroshi Takaku
Journal:  Cancer Biol Ther       Date:  2015-09-21       Impact factor: 4.742

5.  Baculovirus capsid display potentiates OVA cytotoxic and innate immune responses.

Authors:  Paula Molinari; María I Crespo; María J Gravisaco; Oscar Taboga; Gabriel Morón
Journal:  PLoS One       Date:  2011-08-30       Impact factor: 3.240

6.  Display of Porcine Epidemic Diarrhea Virus Spike Protein on Baculovirus to Improve Immunogenicity and Protective Efficacy.

Authors:  Chia-Yu Chang; Wei-Ting Hsu; Yu-Chan Chao; Hui-Wen Chang
Journal:  Viruses       Date:  2018-06-27       Impact factor: 5.048

7.  Recombinant neuraminidase pseudotyped baculovirus: a dual vector for delivery of Angiotensin II peptides and DNA vaccine.

Authors:  Irisa Trianti; Saengchai Akeprathumchai; Phenjun Mekvichitsaeng; Sansanalak Rachdawong; Kanokwan Poomputsa
Journal:  AMB Express       Date:  2018-10-16       Impact factor: 3.298

Review 8.  Baculovirus-mediated gene delivery and RNAi applications.

Authors:  Kaisa-Emilia Makkonen; Kari Airenne; Seppo Ylä-Herttulala
Journal:  Viruses       Date:  2015-04-22       Impact factor: 5.048

Review 9.  Recent Progress towards Novel EV71 Anti-Therapeutics and Vaccines.

Authors:  Qingyong Ng; Fang He; Jimmy Kwang
Journal:  Viruses       Date:  2015-12-08       Impact factor: 5.048

Review 10.  The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road.

Authors:  Cleo Goyvaerts; Karine Breckpot
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.